Tarsus Pharmaceuticals, Inc. (TARS) Latest Filing Signal

Latest Filing: 10-K  |  Filed Feb 23, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Tarsus Pharmaceuticals, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Tarsus Pharmaceuticals, Inc.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
-3.78%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Positive
GEMINI
Continuing Positive
CLAUDE
Turned Positive
CHATGPT
Continuing Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Tarsus Pharmaceuticals, Inc. actually do?
Answer:
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapeutics, primarily in eye care. The company launched XDEMVY(R) (lotilaner ophthalmic solution) 0.25% in August 2023 for the treatment of Demodex blepharitis, a condition caused by Demodex mite infestation, for which it is the first and only FDA-approved therapeutic. Tarsus is also advancing its pipeline with lotilaner API for other indications, including TP-04 for ocular rosacea and TP-05 for Lyme disease prophylaxis. The company's strategy centers on creating new markets in eye care by addressing the root cause of diseases and expanding its pipeline into areas with high unmet medical needs.
Question:
What are Tarsus Pharmaceuticals, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by net product sales of XDEMVY. License fees and collaboration revenue are also generated from out-license agreements.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required